Panbela Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 8
- Market Cap
- -
- Website
- http://www.panbela.com
First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer
Panbela Therapeutics enrolls first patient in Phase I trial of CPP-1X-S (eflornithine sachets) for STK11 mutant NSCLC, aiming to determine the maximum tolerated dose in combination with Keytruda. The trial, led by Moffitt Cancer Center, seeks to evaluate efficacy and safety, with Phase II expected to start in 2024.
Related Clinical Trials:
© Copyright 2024. All Rights Reserved by MedPath